Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Alhava

Showing results (131-140 of 221) with videos related to

Pageof 23
Sort By:
Anticancer Research|September 1, 1992
Clinical, histological and quantitative prognostic factors in cutaneous malignant melanomaJ Karjalainen, M Eskelinen, V M Kosma, et al.
Scandinavian Journal of Gastroenterology|July 1, 1997
Protoporphyrin-IX distribution and photodynamic effect in rat oesophagus after aminolaevulinic acid administrationK Mäkinen, S Grönlund-Pakkanen, M Tiirikainen, et al.
Anticancer Research|May 1, 1993
The value of combined use of serum tumour markers and nuclear magnetic spectroscopy of plasma in the detection of pancreatic cancer among patients with jaundice or cholestasis: results from a prospective studyP A Pasanen, R Kauppinen, M Eskelinen, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|July 29, 2008
Sister's fracture history may be associated with perimenopausal bone fragility and modifies the predictability of fracture riskJ Sirola, K Salovaara, M Tuppurainen, et al.
Anticancer Research|November 1, 1996
Comparison of classic and quantitative prognostic factors in colorectal cancerK Ropponen, M Eskelinen, V M Kosma, et al.
Anticancer Research|November 1, 1992
A prospective study of the value of imaging, serum markers and their combination in the diagnosis of pancreatic carcinoma in symptomatic patientsP A Pasanen, M Eskelinen, K Partanen, et al.
Anticancer Research|September 1, 1992
Clinical value of serum tumour markers CEA, CA 50 and CA 242 in the distinction between malignant versus benign diseases causing jaundice and cholestasis; results from a prospective studyP A Pasanen, M Eskelinen, K Partanen, et al.
British Journal of Cancer|May 1, 1992
Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinomaP A Pasanen, M Eskelinen, K Partanen, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|May 29, 2000
Risk factors for perimenopausal distal forearm fractureR J Honkanen, K Honkanen, H Kröger, et al.
British Journal of Cancer|April 1, 1993
Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer; results from a prospective studyP A Pasanen, M Eskelinen, K Partanen, et al.
Pageof 23

Showing results (131-140 of 221) with videos related to

Sort By:
Pageof 23
Anticancer Research|September 1, 1992
Clinical, histological and quantitative prognostic factors in cutaneous malignant melanomaJ Karjalainen, M Eskelinen, V M Kosma, et al.
Scandinavian Journal of Gastroenterology|July 1, 1997
Protoporphyrin-IX distribution and photodynamic effect in rat oesophagus after aminolaevulinic acid administrationK Mäkinen, S Grönlund-Pakkanen, M Tiirikainen, et al.
Anticancer Research|May 1, 1993
The value of combined use of serum tumour markers and nuclear magnetic spectroscopy of plasma in the detection of pancreatic cancer among patients with jaundice or cholestasis: results from a prospective studyP A Pasanen, R Kauppinen, M Eskelinen, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|July 29, 2008
Sister's fracture history may be associated with perimenopausal bone fragility and modifies the predictability of fracture riskJ Sirola, K Salovaara, M Tuppurainen, et al.
Anticancer Research|November 1, 1996
Comparison of classic and quantitative prognostic factors in colorectal cancerK Ropponen, M Eskelinen, V M Kosma, et al.
Anticancer Research|November 1, 1992
A prospective study of the value of imaging, serum markers and their combination in the diagnosis of pancreatic carcinoma in symptomatic patientsP A Pasanen, M Eskelinen, K Partanen, et al.
Anticancer Research|September 1, 1992
Clinical value of serum tumour markers CEA, CA 50 and CA 242 in the distinction between malignant versus benign diseases causing jaundice and cholestasis; results from a prospective studyP A Pasanen, M Eskelinen, K Partanen, et al.
British Journal of Cancer|May 1, 1992
Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinomaP A Pasanen, M Eskelinen, K Partanen, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|May 29, 2000
Risk factors for perimenopausal distal forearm fractureR J Honkanen, K Honkanen, H Kröger, et al.
British Journal of Cancer|April 1, 1993
Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer; results from a prospective studyP A Pasanen, M Eskelinen, K Partanen, et al.
Pageof 23